GB563651A - The preparation of physiologically active and antigenic substances - Google Patents

The preparation of physiologically active and antigenic substances

Info

Publication number
GB563651A
GB563651A GB17102/42A GB1710242A GB563651A GB 563651 A GB563651 A GB 563651A GB 17102/42 A GB17102/42 A GB 17102/42A GB 1710242 A GB1710242 A GB 1710242A GB 563651 A GB563651 A GB 563651A
Authority
GB
United Kingdom
Prior art keywords
virus
basic
substances
protamines
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB17102/42A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of GB563651A publication Critical patent/GB563651A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Antigenic substances, vaccines, &c. are obtained by mixing a virus in active, attenuated or inactivated state with a basic-protein precipitant comprising basic proteins such as the protamines, histones, globins, basic degradation products of protamines (e.g. protones), polypeptides, basic amino acids (e.g. arginine, histidine, lysine, citralline), histone esters or hydrolysates, decarboxy - polypeptides. The virus substances treated include brain emulsions and other fluids from infected animals; undesired materials may be eliminated by dialysis and the virus may be attenuated or inactivated by known methods. The precipitate produced by the reaction between the virus and the precipitant may be dialyzed to remove any dialysyable substances remaining, washed (e.g. with a dilute protamine solution), centrifuged and dried under vacuum. The viruses of influenza, yellow fever, rabies and equine encephalomyetitis in particular may be treated as described.
GB17102/42A 1941-12-05 1942-12-01 The preparation of physiologically active and antigenic substances Expired GB563651A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US563651XA 1941-12-05 1941-12-05

Publications (1)

Publication Number Publication Date
GB563651A true GB563651A (en) 1944-08-24

Family

ID=22003909

Family Applications (1)

Application Number Title Priority Date Filing Date
GB17102/42A Expired GB563651A (en) 1941-12-05 1942-12-01 The preparation of physiologically active and antigenic substances

Country Status (1)

Country Link
GB (1) GB563651A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010901A2 (en) * 1999-08-11 2001-02-15 Symbiotec Gmbh Antimicrobial histone h1 compositions, kits, and methods of use thereof
US6884423B1 (en) 1998-08-13 2005-04-26 Symbiotec Gmbh Antimicrobial histone H1 compositions, kits, and methods of use thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565854B2 (en) 1998-08-13 2003-05-20 Philadelphia Health And Education Corporation Antimicrobial histone H1 compositions, kits, and methods of use thereof
US6884423B1 (en) 1998-08-13 2005-04-26 Symbiotec Gmbh Antimicrobial histone H1 compositions, kits, and methods of use thereof
WO2001010901A2 (en) * 1999-08-11 2001-02-15 Symbiotec Gmbh Antimicrobial histone h1 compositions, kits, and methods of use thereof
WO2001010901A3 (en) * 1999-08-11 2001-08-09 Symbiotec Gmbh Antimicrobial histone h1 compositions, kits, and methods of use thereof

Similar Documents

Publication Publication Date Title
CY1115749T1 (en) SWINE CYCLE, NUCLEAR ACIDS, POLYPALPTES AND VACCINES
RU2018130813A (en) FMDV VACCINES BASED ON RECOMBINANT Adenovirus VECTOR AND THEIR APPLICATION
Bang Filamentous forms of Newcastle virus
WO2015050181A1 (en) Injectable vaccine composition
Kurrle et al. Influenza virus‐specific T cell‐mediated cytotoxicity: integration of the virus antigen into the target cell membrane is essential for target cell formation
Russell et al. Cell cooperation in antibody responses to influenza virus. I. Priming of helper T cells by internal components of the virion
ES379641A1 (en) Ethylethyleneimine as an inactivation agent
RU2017146398A (en) EXOSOMA AND THEIR APPLICATION AS A VACCINE
SE9903031D0 (en) Peptide mixture and vaccine against a chronic viral infection
DE68925660D1 (en) HIV peptide fragments
GB563651A (en) The preparation of physiologically active and antigenic substances
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
EA202000369A1 (en) EXPRESSION VECTOR FOR CREATION OF IMMUNOBIOLOGICAL AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 (VERSIONS)
BR112017024283A8 (en) VACCINES AGAINST DENGUE
ES2063897T5 (en) VACCINE AGAINST PORCINE AND DIAGNOSTIC CHOLERA VIRUS.
US2445300A (en) Virus vaccines
US2399443A (en) Desiccated virus vaccines and process of producing same
SE7500130L (en)
Sacherl et al. Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance
Quigley Ultrafiltration and ultracentrifugation studies of Coxsackie virus.
EP3185901B1 (en) Compound and method
JP3017887B2 (en) Methods for inactivating prionene, viruses and other infectious agents
Bui et al. Schistosoma mansoni soluble egg antigens enhance Listeria monocytogenes vector HIV-1 vaccine induction of cytotoxic T cells
GB1442564A (en) Process for preparing inactivated hb ag vaccine
OSHIMA et al. Studies on some strains of tobacco mosaic virus pathogenic to crucifer plants 1. Physical and chemical studies